Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Eli Lilly and Company
Pfizer
Pfizer
University of Maryland, Baltimore
AstraZeneca
University of Vermont
University of Oxford
Boehringer Ingelheim
Abramson Cancer Center at Penn Medicine
AstraZeneca
University of Southern California
National Cancer Institute (NCI)
University of Vermont
Tesaro, Inc.
AbbVie
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC
Peking University Cancer Hospital & Institute
Shanghai Junshi Bioscience Co., Ltd.
Daiichi Sankyo
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Innovent Biologics (Suzhou) Co. Ltd.
AstraZeneca
Sichuan University
Eli Lilly and Company
The Netherlands Cancer Institute
Memorial Sloan Kettering Cancer Center
Taiho Pharmaceutical Co., Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Bristol-Myers Squibb
Celgene
University of Chicago
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Shanghai Jiao Tong University School of Medicine
Emory University
M.D. Anderson Cancer Center
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Innovent Biologics (Suzhou) Co. Ltd.
Roswell Park Cancer Institute
Memorial Sloan Kettering Cancer Center
Case Comprehensive Cancer Center
Innovent Biologics (Suzhou) Co. Ltd.
Novartis
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Bayer